Trial Profile
Long-term population-based outcomes of adjuvant trastuzumab in HER2-positive early breast cancer: The British Columbia experience.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2014
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 26 May 2014 New trial record